Annexon becomes the latest group to provide a confusing update in Huntington's disease

Annexon Biosciences believes that inhibiting complement could stop Huntington’s disease in its tracks. However, after what it called “promising” interim mid-stage data yesterday, the jury is still out on its lead project, ANX005.